Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort Shelley Ji Eun Hwang, MBBS (Hons), Giuliana Carlos, MBBS, Deepal Wakade, MD, Karen Byth, PhD, Benjamin Y. Kong, MBBS, Shaun Chou, MBBS, Matteo S. Carlino, MBBS, FRACP, Richard Kefford, MBBS, PhD, FRACP, Pablo Fernandez-Penas, MD, PhD, FACD Journal of the American Academy of Dermatology Volume 74, Issue 3, Pages 455-461.e1 (March 2016) DOI: 10.1016/j.jaad.2015.10.029 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Estimated cumulative incidence of developing the first lichenoid reactions (A), eczema (B), and vitiligo (C) by months since commencement of treatment. Tick marks represent censored observations. Journal of the American Academy of Dermatology 2016 74, 455-461.e1DOI: (10.1016/j.jaad.2015.10.029) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions